BiotechTube

Abobotulinum toxin A

Pre-clinicalUNKNOWN
0 watching 0 views this week💤 Quiet
20
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Tourette Syndrome

Conditions

Tourette Syndrome, Chronic Vocal Tic

Trial Timeline

Jan 1, 2014 → —

NCT ID
NCT02187679

About Abobotulinum toxin A

Abobotulinum toxin A is a pre-clinical stage product being developed by Ipsen for Tourette Syndrome. The current trial status is unknown. This product is registered under clinical trial identifier NCT02187679. Target conditions include Tourette Syndrome, Chronic Vocal Tic.

Hype Score Breakdown

Clinical
5
Activity
2
Company
7
Novelty
2
Community
1

Clinical Trials (2)

NCT IDPhaseStatus
NCT03136341ApprovedRecruiting
NCT02187679Pre-clinicalUNKNOWN

Competing Products

12 competing products in Tourette Syndrome

See all competitors
ProductCompanyStageHype Score
AZD5213 and placeboAstraZenecaPhase 2
52
PF-03654746 + Placebo + Placebo + PF-03654746PfizerPhase 2
51
AripiprazoleBristol Myers SquibbPre-clinical
22
NBI-98854Neurocrine BiosciencesPhase 2
49
Valbenazine + Placebo oral capsuleNeurocrine BiosciencesPhase 2
49
ValbenazineNeurocrine BiosciencesPhase 2
49
NBI-98854Neurocrine BiosciencesPhase 1
30
Valbenazine + Placebo oral capsuleNeurocrine BiosciencesPhase 2
49
NBI-98854 + PlaceboNeurocrine BiosciencesPhase 2
49
ValbenazineNeurocrine BiosciencesPhase 2
49
NBI-98854 + PlaceboNeurocrine BiosciencesPhase 2
49
Tetrabenazine MR + PlaceboBausch HealthPhase 2
47

Other Products from Ipsen

AbobotulinumtoxinA + PlaceboApproved
82
lanreotide acetateApproved
82
Tigan® + PlaceboApproved
82
Diosmectite (Smecta®)Approved
82
lanreotide (Autogel formulation)Approved
82